Barclays Forecasts Strong Price Appreciation for LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group (NASDAQ:LFST - Free Report) had its price target lifted by Barclays from $6.00 to $7.00 in a research report sent to investors on Monday,Benzinga reports. They currently have an underweight rating on the stock.

Separately, UBS Group lowered their price target on LifeStance Health Group from $9.00 to $7.50 and set a "neutral" rating for the company in a report on Thursday, August 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $8.42.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST traded up $0.03 during trading on Monday, reaching $7.39. The company had a trading volume of 2,020,173 shares, compared to its average volume of 1,506,957. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $2.83 billion, a PE ratio of -27.73 and a beta of 1.24. LifeStance Health Group has a twelve month low of $4.64 and a twelve month high of $9.20. The stock has a 50-day moving average price of $6.92 and a two-hundred day moving average price of $6.21.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.05. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.67%. The company had revenue of $312.70 million for the quarter, compared to analyst estimates of $302.25 million. During the same period in the prior year, the firm earned ($0.17) EPS. The firm's quarterly revenue was up 18.9% on a year-over-year basis. As a group, sell-side analysts predict that LifeStance Health Group will post -0.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Ann Varanakis sold 5,269 shares of the firm's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $6.28, for a total value of $33,089.32. Following the transaction, the insider now owns 263,007 shares of the company's stock, valued at approximately $1,651,683.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 6.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LifeStance Health Group

Several hedge funds and other institutional investors have recently bought and sold shares of LFST. CIBC Asset Management Inc purchased a new stake in shares of LifeStance Health Group during the second quarter valued at approximately $53,000. Bessemer Group Inc. lifted its holdings in LifeStance Health Group by 43.4% in the 1st quarter. Bessemer Group Inc. now owns 9,143 shares of the company's stock worth $56,000 after buying an additional 2,768 shares in the last quarter. Algert Global LLC purchased a new position in LifeStance Health Group in the 2nd quarter valued at about $57,000. Victory Capital Management Inc. grew its stake in shares of LifeStance Health Group by 27.0% during the second quarter. Victory Capital Management Inc. now owns 14,407 shares of the company's stock valued at $71,000 after acquiring an additional 3,063 shares in the last quarter. Finally, Park Edge Advisors LLC purchased a new stake in shares of LifeStance Health Group during the third quarter worth about $73,000. 85.50% of the stock is owned by institutional investors and hedge funds.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.